MicroRNAs in B-cell lymphomas: how a complex biology gets more complex
Tóm tắt
Từ khóa
Tài liệu tham khảo
O'Connell RM, Baltimore D . MicroRNAs and hematopoietic cell development. Curr Top Dev Biol 2012; 99: 145–174.
Mraz M, Kipps TJ . MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54: 1836–1839.
Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007; 27: 847–859.
Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008; 132: 860–874.
Mraz M, Dolezalova D, Plevova K, Kozubik KS, Mayerova V, Cerna K et al. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood 2012; 119: 2110–2113.
Ebert MS, Sharp PA . Roles for microRNAs in conferring robustness to biological processes. Cell 2012; 149: 515–524.
Akbari Moqadam F, Pieters R, den Boer ML . The hunting of targets: challenge in miRNA research. Leukemia 2013; 27: 16–23.
Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 2010; 115: 1768–1778.
Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP . The impact of microRNAs on protein output. Nature 2008; 455: 64–71.
Friedman RC, Farh KK, Burge CB, Bartel DP . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92–105.
Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbiani DF et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 2008; 28: 630–638.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524–15529.
Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28–40.
Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103: 2257–2261.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828–833.
Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103: 7024–7029.
Costinean S, Sandhu S, Pedersen I, Tili E, Trotta R, Perrotti D et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 2009; 114: 1374–1382.
Medina PP, Nolde M, Slack FJ . OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467: 86–90.
Sandhu SK, Fassan M, Volinia S, Lovat F, Balatti V, Pekarsky Y et al. B-cell malignancies in microRNA Emu-miR-17~92 transgenic mice. Proc Natl Acad Sci USA 2013; 110: 18208–18213.
Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci USA 2010; 107: 12210–12215.
Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 2014; 124: 546–554.
Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K et al. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood 2014; 124: 84–95.
Lawrie C, Soneji S, Marafioti T, Cooper C, Palazzo S, Paterson J et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 2007; 121: 1156–1161.
Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Brit J Haematol 2008; 141: 672–675.
Di Lisio L, Gomez-Lopez G, Sanchez-Beato M, Gomez-Abad C, Rodriguez ME, Villuendas R et al. Mantle cell lymphoma: transcriptional regulation by microRNAs. Leukemia 2010; 24: 1335–1342.
Zhao JJ, Lin JH, Lwin T, Yang H, Guo JP, Kong W et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115: 2630–2639.
Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 2009; 23: 1159–1163.
O'Carroll D, Mecklenbrauker I, Das PP, Santana A, Koenig U, Enright AJ et al. A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev 2007; 21: 1999–2004.
Seda V, Mraz M . B cell receptor (BCR) signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol 2014; e-pub ahead of print 1 August 2014 doi:10.1111/ejh.12427.
Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ et al. Targeted deletion reveals essential and overlapping functions of the miR-17∼92 family of miRNA clusters. Cell 2008; 132: 875–886.
Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405–414.
Belver L, de Yébenes VG, Ramiro AR . MicroRNAs prevent the generation of autoreactive antibodies. Immunity 2010; 33: 713–722.
Xu S, Guo K, Zeng Q, Huo J, Lam KP . The RNase III enzyme Dicer is essential for germinal center B-cell formation. Blood 2012; 119: 767–776.
Rao DS, O'Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, Baltimore D . MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 2010; 33: 48–59.
Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007; 131: 146–159.
Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF . miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci USA 2007; 104: 7080–7085.
van den Berg A, Kroesen BJ, Kooistra K, de Jong D, Briggs J, Blokzijl T et al. High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Gene Chromosome Cancer 2003; 37: 20–28.
Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316: 608–611.
Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y et al. Regulation of the germinal center response by microRNA-155. Science 2007; 316: 604–608.
Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R et al. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 2008; 28: 621–629.
de Yebenes VG, Belver L, Pisano DG, Gonzalez S, Villasante A, Croce C et al. miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med 2008; 205: 2199–2206.
Tan LP, Wang M, Robertus JL, Schakel RN, Gibcus JH, Diepstra A et al. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest 2009; 89: 708–716.
Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T . Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735–739.
Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T . Identification of novel genes coding for small expressed RNAs. Science 2001; 294: 853–858.
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793–1801.
Kminkova J, Mraz M, Zaprazna K, Navrkalova V, Tichy B, Plevova K et al. Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia. Carcinogenesis 2014; 35: 992–1002.
Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008; 105: 5166–5171.
Lia M, Carette A, Tang H, Shen Q, Mo T, Bhagat G et al. Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. Blood 2012; 119: 2981–2990.
Mraz M, Pospisilova S, Malinova K, Slapak I, Mayer J . MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 2009; 50: 506–509.
Mraz M, Pospisilova S . MicroRNAs in chronic lymphocytic leukemia: from causality to associations and back. Expert Rev Hematol 2012; 5: 579–581.
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944–13949.
Mott JL, Kobayashi S, Bronk SF, Gores GJ . mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133–6140.
Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66: 11590–11593.
Zenz T, Mohr J, Eldering E, Kater AP, BĂĽhler A, Kienle D et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009; 113: 3801–3808.
Asslaber D, Pinon JD, Seyfried I, Desch P, Stöcher M, Tinhofer I et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 2010; 115: 4191–4197.
Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 2703–2708.
He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130–1134.
Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 2011; 118: 3072–3079.
Tili E, Michaille JJ, Luo Z, Volinia S, Rassenti LZ, Kipps TJ et al. The downregulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood 2012; 120: 2631–2638.
Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011; 305: 59–67.
Baer C, Claus R, Frenzel LP, Zucknick M, Park YJ, Gu L et al. Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microrna expression in chronic lymphocytic leukemia. Cancer Res 2012; 72: 3775–3785.
Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119: 1162–1172.
O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT . c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839–843.
Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P et al. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 2009; 23: 2806–2811.
Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009; 23: 2839–2849.
Olive V, Sabio E, Bennett MJ, De Jong CS, Biton A, McGann JC et al. A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. Elife 2013; 2: e00822.
Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G et al. The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2012; 26: 1064–1072.
Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K . MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 2009; 113: 396–402.
Lawrie CH, Chi JX, Taylor S, Tramonti D, Ballabio E, Palazzo S et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 2009; 13: 1248–1260.
Fassina A, Marino F, Siri M, Zambello R, Ventura L, Fassan M et al. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest 2012; 92: 1574–1582.
Olive V, Li Q, He L . mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev 2013; 253: 158–166.
Eis P, Tam W, Sun L, Chadburn A, Li Z, Gomez M et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005; 102: 3627–3632.
Roehle A, Hoefig K, Repsilber D, Thorns C, Ziepert M, Wesche K et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol 2008; 142: 732–744.
Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood 2011; 117: 3816–3825.
Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009; 113: 3754–3764.
Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, Chinichian S et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011; 17: 4125–4135.
Thompson RC, Vardinogiannis I, Gilmore TD . Identification of an NF-kappaB p50/p65-responsive site in the human MIR155HG promoter. BMC Mol Biol 2013; 14: 24.
Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M . Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res 2008; 36: 6608–6619.
Thompson RC, Herscovitch M, Zhao I, Ford TJ, Gilmore TD . NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem 2011; 286: 1675–1682.
Dagan LN, Jiang X, Bhatt S, Cubedo E, Rajewsky K, Lossos IS . miR-155 regulates HGAL expression and increases lymphoma cell motility. Blood 2012; 119: 513–520.
Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC . Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010; 107: 3111–3116.
Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA 2012; 109: E1695–E1704.
Vigorito E, Kohlhaas S, Lu D, Leyland R . miR-155: an ancient regulator of the immune system. Immunol Rev 2013; 253: 146–157.
Thapa DR, Bhatia K, Bream JH, D'Souza G, Rinaldo CR, Wolinsky S et al. B-cell activation induced microRNA-21 is elevated in circulating B cells preceding the diagnosis of AIDS-related non-Hodgkin lymphomas. AIDS 2012; 26: 1177–1180.
Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S et al. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. Leukemia 2012; 26: 2343–2352.
Ma X, Kumar M, Choudhury SN, Becker Buscaglia LE, Barker JR, Kanakamedala K et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci USA 2011; 108: 10144–10149.
Barnes NA, Stephenson S, Cocco M, Tooze RM, Doody GM . BLIMP-1 and STAT3 counterregulate microRNA-21 during plasma cell differentiation. J Immunol 2012; 189: 253–260.
Bai H, Wei J, Deng C, Yang X, Wang C, Xu R . MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol 2013; 97: 223–231.
Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo YM, Iwamoto K et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 2009; 114: 3265–3275.
Gu L, Song G, Chen L, Nie Z, He B, Pan Y et al. Inhibition of miR-21 induces biological and behavioral alterations in diffuse large B-cell lymphoma. Acta Haematol 2013; 130: 87–94.
Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010; 116: 945–952.
Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011; 117: 3140–3146.
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K . STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39: 493–506.
Navarro A, Clot G, Prieto M, Royo C, Vegliante MC, Amador V et al. microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics. Clin Cancer Res 2013; 19: 3121–3129.
He M, Gao L, Zhang S, Tao L, Wang J, Yang J et al. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL. Gastric Cancer 2013; 17: 431–441.
Zauli G, Voltan R, di Iasio MG, Bosco R, Melloni E, Sana ME et al. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011; 17: 2712–2724.
Boysen J, Sinha S, Price-Troska T, Warner SL, Bearss DJ, Viswanatha D et al. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. Leukemia 2014; 28: 451–455.
Yamakuchi M, Ferlito M, Lowenstein CJ . miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421–13426.
Li L, Yuan L, Luo J, Gao J, Guo J, Xie X . MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med 2013; 13: 109–117.
Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, Rehrauer H et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011; 117: 6227–6236.
Rizzo M, Mariani L, Cavallini S, Simili M, Rainaldi G . The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation. Nucleic Acid Ther 2012; 22: 283–288.
Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 2011; 30: 2587–2594.
Chen S, Wang Z, Dai X, Pan J, Ge J, Han X et al. Re-expression of microRNA-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro. Cancer Sci 2013; 104: 826–834.
Thomas MD, Kremer CS, Ravichandran KS, Rajewsky K, Bender TP . c-Myb is critical for B cell development and maintenance of follicular B cells. Immunity 2005; 23: 275–286.
Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS . Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004; 104: 2933–2935.
Brown P, Marafioti T, Kusec R, Banham AH . The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma. J Mol Histol 2005; 36: 249–256.
Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 2490–2497.
Tano N, Kim HW, Ashraf M . microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4. PLoS One 2011; 6: e23114.
Watanabe A, Tagawa H, Yamashita J, Teshima K, Nara M, Iwamoto K et al. The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia 2011; 25: 1324–1334.
Bryniarski K, Ptak W, Jayakumar A, Pullmann K, Caplan MJ, Chairoungdua A et al. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J Allergy Clin Immunol 2013; 132: 170–181.
Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S et al. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell 2012; 22: 524–535.
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169.
Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol 2011; 155: 53–64.
Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC et al. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia 2011; 25: 145–152.
Lwin T, Lin J, Choi YS, Zhang X, Moscinski LC, Wright KL et al. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 2010; 116: 5228–5236.
Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B et al. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest 2013; 123: 4612–4626.
Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A . The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood 2013; 122: 4220–4229.
Li Z, Rana TM . Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 2014; 13: 622–638.
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685–1694.
Beg MBA, Sachdev J, Borad M, Cortes J, Tibes R, Kang Y et al. A Phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis (Late Breaking Abstract, 4LBA). 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics: Barcelona, Spain, 2014.
Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Muller A . Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 2012; 26: 2421–2424.
Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012; 18: 6260–6270.
Salerno E, Scaglione BJ, Coffman FD, Brown BD, Baccarini A, Fernandes H et al. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol Cancer Ther 2009; 8: 2684–2692.
Arora S, Swaminathan SK, Kirtane A, Srivastava SK, Bhardwaj A, Singh S et al. Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. Int J Nanomedicine 2014; 9: 2933–2942.
Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM et al. LNA-mediated anti-microRNA-155 silencing in low-grade B cell lymphomas. Blood 2012; 120: 1678–1686.
Dereani S, Macor P, D'Agaro T, Mezzaroba N, Dal-Bo M, Capolla S et al. Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. J Hematol Oncol 2014; 7: 79.
Spierings DC, McGoldrick D, Hamilton-Easton AM, Neale G, Murchison EP, Hannon GJ et al. Ordered progression of stage-specific miRNA profiles in the mouse B2 B-cell lineage. Blood 2011; 117: 5340–5349.
Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 2010; 116: e118–e127.
Chen RW, Bemis LT, Amato CM, Myint H, Tran H, Birks DK et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 2008; 112: 822–829.